Effect of Mass Deworming on Child Growth

This study has been completed.
Sponsor:
Collaborators:
Ministry of Health, Uganda
World Bank
Information provided by:
Makerere University
ClinicalTrials.gov Identifier:
NCT00344669
First received: June 14, 2006
Last updated: October 16, 2006
Last verified: June 2006
  Purpose

The purpose of the study was to determine whether periodical mass deworming improves growth in children below six years of age.


Condition Intervention
Low Weight for Age in Preschool Children
Drug: Albendazole 400 mg, given 6 monthly

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind
Primary Purpose: Treatment
Official Title: Increased Weight Gain in Preschool Children Due to Mass Albendazole Treatment Given During "Child Health Days" in Uganda

Resource links provided by NLM:


Further study details as provided by Makerere University:

Primary Outcome Measures:
  • weight gain
  • weight for age

Estimated Enrollment: 10000
Study Start Date: August 2000
Estimated Study Completion Date: November 2003
Detailed Description:

Many children in developing countries get slowed growth because of heavy loads of intestinal helminths. Quite often treatment is not sought because there may not be any obvious symptoms. Slowed growth may manifest as low weight for age or low height for age.

The objective of the study was to estimate the effectiveness of the delivery of an anthelmintic drug through a community child health program on the weight gain of preschool aged children.

Design: This was a cluster randomized controlled trial in 48 parishes in Eastern Uganda. All 48 parishes were participating in a new program for child health; 24 were randomly assigned to offer to children an additional service of anthelmintic treatment. The intervention was 400 mg of albendazole added to the standard services at child days over a 3 years period. All children were offered the drug and the main outcome measure was weight gain.

Results: A total of 27,995 children were recruited into the 2 arms of the study with 14,940 in the treatment arm and 13,055 in the control arm. The intervention arm got an increase in weight gain of about 10% (166 grams per child per year (CI: 16-316) above expected weight gain when treatment was taken twice a year and an increase of 5% when treatment was received approximately annually.

Conclusion: The inclusion of deworming in regularly scheduled health services appears practical and capable of increasing child growth.

  Eligibility

Ages Eligible for Study:   1 Year to 7 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • children 1-6 years

Exclusion Criteria:

-

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00344669

Locations
Uganda
48 parishes in Eastern Uganda
Kampala, Uganda
Sponsors and Collaborators
Makerere University
Ministry of Health, Uganda
World Bank
Investigators
Principal Investigator: Joseph K Konde-Lule, MD DPH MSc Makerere University
Study Chair: John F Mutumba, MBChB, MSc Ministry of Health, Uganda
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00344669     History of Changes
Other Study ID Numbers: P05267
Study First Received: June 14, 2006
Last Updated: October 16, 2006
Health Authority: Uganda: National Council for Science and Technology

Keywords provided by Makerere University:
underweight
preschool
mass deworming

Additional relevant MeSH terms:
Albendazole
Anthelmintics
Anti-Infective Agents
Anticestodal Agents
Antimitotic Agents
Antineoplastic Agents
Antiparasitic Agents
Antiplatyhelmintic Agents
Antiprotozoal Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses
Tubulin Modulators

ClinicalTrials.gov processed this record on October 23, 2014